The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2015

Filed:

Jul. 08, 2011
Applicants:

Dana T. Aftab, San Rafael, CA (US);

Carlos L. Arteaga, Nashville, TN (US);

Veronique Blanc, Paris, FR;

Anindita Chakrabarty, Nashville, TN (US);

Marielle Chiron-blonde, Paris, FR;

Celine Nicolazzi, Choisy le Roi, FR;

Ariella Hanker, Nashville, TN (US);

Loic Vincent, Evry, FR;

Inventors:

Dana T. Aftab, San Rafael, CA (US);

Carlos L. Arteaga, Nashville, TN (US);

Veronique Blanc, Paris, FR;

Anindita Chakrabarty, Nashville, TN (US);

Marielle Chiron-Blonde, Paris, FR;

Celine Nicolazzi, Choisy le Roi, FR;

Ariella Hanker, Nashville, TN (US);

Loic Vincent, Evry, FR;

Assignee:

Exelixis, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/498 (2006.01); A01N 43/58 (2006.01); A01N 43/60 (2006.01); A61K 31/50 (2006.01); A61K 31/495 (2006.01); A61K 31/517 (2006.01); A61K 31/63 (2006.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/498 (2013.01); A61K 31/517 (2013.01); A61K 31/63 (2013.01); A61K 31/7088 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/34 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.


Find Patent Forward Citations

Loading…